CHMP adopts positive opinion for treatment of acute angioedema attacks in children with hereditary angioedema with RUCONEST®
Pharming Group N.V. announces the Committee for Medicinal Products for Human Use (CHMP), an advisory committee of the European Medicine Agency (EMA), has adopted a positive opinion recommending an extension of the indication for RUCONEST® to the European Commission.
''As we continue to see increasing demand for RUCONEST® in the treatment of HAE, we are pleased to announce this step forward in this paediatric label expansion. This will enable us to treat attacks of patients of all ages living with HAE in the EU''- Sijmen de Vries - CEO
Wilt u overschakelen naar een andere taal? Klik hier voor de Nederlandse website.